Short answer: on 9 November 2026 the US medicines regulator, the FDA, told the makers of every GLP-1 medicine, Mounjaro (tirzepatide) included, to add a warning about NAION, a rare eye condition that causes a sudden, painless loss of vision, usually in one eye.
It is rare with or without the medicine. In the FDA's analysis of 126 clinical trials there were about 6 cases a year for every 100,000 people on a GLP-1 medicine, against about 4 for people on a placebo or another diabetes medicine.
The FDA calls it a potential increased risk. Its figures show more cases in people taking these medicines; they do not prove the medicines were the cause.
In the UK, the product information for Wegovy already lists NAION as very rare, and Mounjaro's does not list it as of November 2026. Whichever you take, a sudden loss of vision, or of part of your field of vision, needs eye casualty or A&E the same day.
This guide sets out what the FDA announced, what it means in the UK, the figures behind it and what to do if your eyesight changes, as of November 2026.
What has the FDA said about Mounjaro and your eyes?
The FDA said on 9 November 2026 that it is requiring the makers of all GLP-1 medicines to add information about a potential increased risk of NAION to their US prescribing information.
Its list names tirzepatide (Mounjaro, and Zepbound in the US), semaglutide (Wegovy, Ozempic and Rybelsus) and orforglipron (Foundayo), with the older medicines liraglutide, dulaglutide, exenatide and lixisenatide.
It goes in the Warnings and Precautions section of that document, which prescribers and pharmacists work from. The notice does not describe it as a boxed warning.
The FDA regulates medicines in the United States. UK packs and leaflets are regulated by the MHRA, so the announcement changes nothing in the UK by itself.

How the warning came about
- July 2024
A study from one US eye hospital reports more NAION in people prescribed semaglutide. The FDA says it prompted its review.
- June 2025
The European Medicines Agency concludes that NAION is a very rare side effect of semaglutide.
- February 2026
The MHRA issues a UK Drug Safety Update on semaglutide and says it is reviewing other GLP-1 medicines.
- November 2026
The FDA requires a warning for every GLP-1 medicine in the US, tirzepatide included.
What is NAION?
NAION (non-arteritic anterior ischaemic optic neuropathy) is a sudden loss of vision caused by reduced blood flow to the front of the optic nerve. It usually affects one eye, and it is painless.
The FDA lists these symptoms:
- a sudden, painless loss of vision in one eye, which you may notice on waking
- blurred or missing parts of your vision, such as blind spots or tunnel vision
- colours looking distorted
- blurry or hazy central vision
The FDA says to contact a healthcare professional straight away with any of them. A sudden loss of vision means eye casualty or A&E: the steps further down say what to do.
The loss of vision can be permanent. The FDA says that once NAION has happened in one eye, the risk in the other eye is higher.
NAION also happens in people who have never taken a GLP-1 medicine. Between them, the FDA and the MHRA name diabetes, high blood pressure, high cholesterol, smoking, sleep apnoea, anaemia and kidney disease as risk factors.
Several of those are common in people who are prescribed these medicines, which is one reason the link is hard to study.
How common is NAION with Mounjaro and other GLP-1 medicines?
It is rare. The chart shows the FDA's figures from 126 clinical trials of GLP-1 medicines taken together. Its notice gives no separate figure for Mounjaro.
- Taking a GLP-1 medicine6.4
- Taking a placebo or another diabetes medicine3.8
- Adults over 50 in general, across published studies2.3 to 10.2
Those rates come from 15 probable cases among 134,253 people: 10 in people on a GLP-1 medicine and 5 in people on a placebo. With so few cases, the gap between the bars is an estimate, not a precise measure.
The FDA also studied health data for US adults with type 2 diabetes who started a new medicine between 2019 and 2024.
- A GLP-1 medicine30 to 32
- An SGLT-2 inhibitor31
- A DPP-4 inhibitor26
The bars are simple rates. When the FDA compared the groups directly, it found an increase against DPP-4 inhibitors and no statistically significant increase against SGLT-2 inhibitors. Both results are in the chart of studies below.
The rates are higher for every group than in the trials. The FDA does not say why, and the two sets of figures were gathered in different ways, so they should not be compared.
Everyone in this study had type 2 diabetes, where the MHRA puts the background rate at 11.4 to 82 cases a year for every 100,000 people.
For semaglutide, the UK and European regulators describe the risk another way: about twice as high in adults with type 2 diabetes, or about one extra case for every 10,000 people treated for a year.
By 1 August 2025 the MHRA had received three Yellow Card reports suggestive of NAION with semaglutide, against about 10.2 million packs dispensed in five years. A report does not prove the medicine was the cause.
Can Mounjaro cause blindness?
It is not known for certain, and if it can, it is rare. The FDA's words are a "potential increased risk", for GLP-1 medicines as a group, of NAION, which can cause permanent loss of vision in the eye it affects.
Blindness is not listed as a side effect in Mounjaro's UK product information.
The FDA acted on its trial figures, its own study of health data, and published studies that it says "consistently reported an increased risk" in people with type 2 diabetes starting a GLP-1 medicine.
It has not said that these medicines cause NAION, and its review of animal studies did not identify how one could lead to it. It does say cases have been reported with every GLP-1 medicine on the market.
What the studies found
The first study, from one US eye hospital in 2024, found a large increase with semaglutide. It studied people already referred to a specialist eye clinic, so it could not show how common NAION is. Larger studies since have found smaller increases, and some found no clear difference.
- Hathaway and colleagues, 20244.28 (1.62 to 11.29)One US eye hospital, 710 people. Semaglutide against other diabetes medicines.
- Grauslund and colleagues, 20242.19 (1.54 to 3.12)Denmark, 424,152 people. Semaglutide against no semaglutide.
- Simonsen and colleagues, 20252.81 (1.67 to 4.75)Denmark and Norway, 61,377 people starting semaglutide. Against SGLT-2 inhibitors.
- Cai and colleagues, 20251.32 (1.14 to 1.54)14 health databases covering 37.1 million people with type 2 diabetes, 810,390 of them starting semaglutide. Time on semaglutide against time off it, in the same people. Its comparisons with three other diabetes medicines mostly found no clear difference.
- Chou and colleagues, 20251.51 (0.71 to 3.25)Health records from 21 countries, 37,314 people with type 2 diabetes and no obesity, after 3 years. Semaglutide against other medicines.
- Chou and colleagues, 20251.19 (0.78 to 1.82)The same study, 130,216 people with type 2 diabetes and obesity, after 3 years.
- Wang and colleagues, 20251.76 (1.01 to 3.07)US health records, 159,398 people. Semaglutide or tirzepatide against other diabetes medicines, older GLP-1 medicines among them.
- FDA Sentinel study, 20261.19 (0.91 to 1.54)US health data, adults starting a medicine between 2019 and 2024. GLP-1 medicines against SGLT-2 inhibitors.
- FDA Sentinel study, 20261.43 (1.02 to 2.01)The same study. GLP-1 medicines against DPP-4 inhibitors.
- Hathaway and colleagues, 20247.64 (2.21 to 26.36)The same eye hospital, 979 people. Semaglutide against other weight-loss medicines.
- Chou and colleagues, 20250.72 (0.24 to 2.16)Health records from 21 countries, 129,690 people with obesity and no type 2 diabetes, after 3 years. Semaglutide against other medicines.
Nearly all of this research is on semaglutide in people with type 2 diabetes. For tirzepatide, and for people taking these medicines for weight management without diabetes, there is far less to go on.
One study counted tirzepatide together with semaglutide: 35 cases of NAION among 79,699 people over two years, against 19 among the same number on other diabetes medicines.
The few studies of tirzepatide on its own draw on health records and on reports of suspected side effects, and none can show whether the risk differs between medicines. The FDA applied the same warning to every GLP-1 medicine.
Is the warning in the UK leaflets for Mounjaro and Wegovy?
For Wegovy, yes. For Mounjaro, not as of 11 November 2026.
| Medicine | What its UK product information says about NAION | Text last revised |
|---|---|---|
| Mounjaro (tirzepatide) | Not listed. Its one eye warning is about diabetic retinopathy. | 29 August 2026 |
| Wegovy injection (semaglutide) | A warning, and a listed side effect: very rare, up to 1 in 10,000 people. Treatment is stopped if NAION is confirmed. | September 2026 |
| Wegovy tablets (semaglutide) | The same warning as the injection. | June 2026 |
| Foundayo (orforglipron) | Says NAION has been reported with GLP-1 medicines, and gives no frequency. | 10 August 2026 |
Not being listed does not mean Mounjaro has been shown to be different: the UK review so far covered semaglutide only.
The MHRA said in its Drug Safety Update of February 2026 that it is "reviewing any evidence for an association with other GLP-1 agonists".
As of 11 November 2026 the MHRA has not announced a change for Mounjaro.
Does Mounjaro affect your eyesight in other ways?
Mounjaro's UK product information lists no eye side effect. Its one eye warning is for people who already have diabetic retinopathy, an eye condition caused by diabetes.
It says a rapid improvement in blood sugar control "has been associated with a temporary worsening of diabetic retinopathy", and that people who have it should be monitored closely. Its leaflet asks you to tell your doctor, pharmacist or nurse before you start if you have diabetic retinopathy or macular oedema.
Blurred vision is not a listed side effect either. The NHS lists it as a symptom of both high and low blood sugar, so with diabetes a change in eyesight can go with a change in blood sugar.
The NHS page on tirzepatide lists vision problems among the signs of low blood sugar, which is more likely if you also take other diabetes medicines. It says not to drive, cycle or use machinery until they pass. Our guide to Mounjaro and type 2 diabetes covers that side of treatment.
| Symptom | What the UK sources say | What to do |
|---|---|---|
| Blurred vision | Not listed for Mounjaro. A symptom of high and of low blood sugar (NHS). | Eye casualty or A&E if it comes on suddenly in one eye or gets worse very quickly. Otherwise an urgent GP appointment or NHS 111. An optician if your sight is getting worse gradually. |
| Diabetic retinopathy getting worse | Can get worse for a time when blood sugar improves quickly (Mounjaro product information). | Tell your diabetes team before you start, and go to every eye screening appointment. |
| Floaters or flashes | Not listed for Mounjaro. Common and not usually serious; floaters can be a later symptom of diabetic retinopathy (NHS). | An urgent opticians appointment or NHS 111 if they are new, come on suddenly, suddenly increase, or come with blurred vision or eye pain. |
| Dry eyes or eye pain | Not listed for Mounjaro. | A pharmacist may be able to help with dry eyes. A painful red eye, or a dark shadow moving across your vision, needs an urgent GP appointment or NHS 111. Sudden severe eye pain, or a red eye with a severe headache and feeling sick, needs A&E or 999. |
What should you do if your vision changes on Mounjaro?
It depends on how the change came on. A sudden loss of vision, or eyesight getting worse very quickly, is a same-day matter whichever medicine you take.
A sudden loss of vision, or eyesight getting worse very quickly: eye casualty or A&E. If you suddenly cannot see from one or both eyes, lose part of your field of vision, or your eyesight gets worse very quickly, stop your treatment and go to eye casualty, where there is one in your area, or A&E. Sudden severe eye pain needs A&E too. Do not drive: ask someone to take you or call 999, and bring your medicines.
Blurred or double vision, flashes, a shadow or eye pain: an urgent GP appointment or NHS 111. The NHS asks for urgent help for changes such as blurred or double vision, flashing lights or shapes, a dark shadow moving across your vision, or a painful eye. If blurring comes on suddenly in one eye or is getting worse quickly, treat it as step 1.
A gradual change: an optician, or your diabetes team. The NHS says to see an optician if you think you may have vision loss. With diabetes, eyesight getting worse over time or difficulty seeing in low light can also go to your GP or diabetes care team. If you take Wegovy, its leaflet says to contact your doctor urgently if your eyesight gets worse, suddenly or gradually.
Say what you take, then tell your pharmacist. Tell whoever examines you that you take Mounjaro and when your last dose was: the MHRA warns that a privately prescribed GLP-1 medicine may not be on your medical record. Then message your pharmacist before your next dose.
Should you stop taking Mounjaro because of the FDA warning?
The FDA has not told people to stop treatment because of the warning. Its advice is to know the symptoms and to contact a healthcare professional straight away if you notice them.
For anyone who develops NAION, it tells prescribers to consider stopping the medicine unless the benefits clearly outweigh the risk. In the UK, semaglutide is stopped if NAION is confirmed.
It adds that anyone who has had NAION before should talk to their prescriber about whether to continue, because the risk of it happening again is higher.
The NHS says to talk to your doctor if you want to stop using tirzepatide, and not to stop suddenly. If you have type 2 diabetes, stopping could affect your blood sugar.
The exception is a sudden loss of vision, or of part of your field of vision: stop your treatment and get help the same day.
Not started treatment yet? Check whether it's suitable for you in a few minutes. A GPhC-registered pharmacist reviews every assessment, and if they can't approve your order, you get a full refund.
Check your eligibilityWhat does Solira ask about your eyes?
Our consultation asks whether you have an eye condition before anything is supplied: glaucoma, diabetic retinopathy, macular degeneration or any other.
We do not start treatment through our service for anyone with proliferative diabetic retinopathy, which needs a diabetes team or GP first. Any other eye condition is marked for your pharmacist to review.
If you have ever had NAION, choose "Yes, other eye condition" so your pharmacist can review it.
The warning sign in this guide was already in the urgent advice every Solira weight-loss patient receives, on Mounjaro and on Wegovy: a sudden loss of vision, or of part of your field of vision, needs a same-day eye assessment.
Already a Solira patient? If you have ever had NAION, or you are told you have it, tell your pharmacist before your next dose so your treatment can be reviewed. If an optician or your diabetes team says your eyes have changed, message your pharmacist through your account before your next order. If the change was sudden, get medical help first.
You can report any suspected side effect, eye problems included, to the MHRA through the Yellow Card scheme.
More on safety: Is Mounjaro safe?, Mounjaro side effects, Is Wegovy safe? and the side effects of each medicine side by side. Our weight loss treatments and safety page have the rest.

